A national database study assessing demographics and clinical characteristics of crohn's disease patients switched to a non-anti-TNF agent after initial primary non-response with anti-TNF agent
Latest Information Update: 21 Dec 2021
At a glance
- Drugs Ustekinumab (Primary) ; Vedolizumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 21 Dec 2021 New trial record
- 27 Oct 2021 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021